BioPharmSignal logoBioPharmSignal

Biotech News

IN8bio Reports Third Quarter 2026 Financial Results and Recent Business Highlights

IN8bio (INAB)IN8bioEarnings

Strengthened research and development (R&D) leadership by appointing Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development Received third-party recognition of INB-619 in a Nature Reviews Drug Discovery review of next-generation immune cell engagers for autoimmune disease Remain

Related news

COGTCogent Biosciences2026-11-05 21:02 EST

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results

LYELLyell Immunopharma2026-11-04 21:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026

URGNUroGen Pharma2026-11-04 13:00 EST

UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights

RLAYRelay Therapeutics2026-10-28 20:12 EST

Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026

IMCRImmunocore Holdings plc2026-11-06 14:00 EST

Immunocore reports third quarter financial results and provides a business update

FATEFate Therapeutics2026-11-05 12:00 EST

Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

RVMDRevolution Medicines2026-11-04 21:02 EST

Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

IDYAIDEAYA Biosciences2026-11-03 11:00 EST

IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update

SNDXSyndax Pharmaceuticals2026-11-02 21:01 EST

Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update

BNTXBioNTech2026-10-20 10:45 EST

BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026

View all latest news

IN8bio

Gamma-Delta T-Cell Therapies IN8bio develops gamma-delta T-cell therapies and T-cell engagers for cancer and autoimmune disease. The platform seeks to use the innate and adaptive properties of gamma-delta T cells to recognize stressed or malignant cells. Glioblastoma Program The company's clinical work in glioblastoma evaluates...

Recent company news

INABIN8bio2026-11-06 21:01 EST

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

INABIN8bio2026-11-05 21:01 EST

IN8bio Reports Third Quarter 2026 Financial Results and Recent Business Highlights

INABIN8bio2026-10-06 20:00 EST

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

INABIN8bio2026-09-22 20:00 EST

IN8bio to Present at Sidoti Small-Cap Virtual Conference

INABIN8bio2026-09-10 12:00 EST

IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference

Stock data

Close
0.83 USD
Market cap
14.96M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States